Islet dysfunction—characterized by a combination of defective insulin secretion,
inappropriately high glucagon secretion and reduced β-cell mass—has a central role in the …

Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to
native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once …

Until recently, the pathogenesis of type 2 diabetes mellitus (T2DM) has been conceptualized
in terms of the predominant defects in insulin secretion and insulin action. It is now …

Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and
currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection …

Importance of the field: Despite the wide array of treatments available, a significant number
of patients with type 2 diabetes continue to remain uncontrolled. The discovery of the incretin …

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide,
a glucagon-like peptide 1 (GLP-1) analog for the treatment of type 2 diabetes mellitus. Data …

The demonstration that the incretin hormone glucagon‐like peptide 1 can improve
glycaemic control in patients with type 2 diabetes has led to the rapid development during …

Liraglutide is a novel glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid
sequence identity to native GLP-1. An amino acid substitution and fatty acid side chain …

Objective: To review the efficacy and safety of liraglutide, marketed as Saxenda, a glucagon-
like peptide-1 analog for obesity management. Data Sources: A MEDLINE search (1970 to …

The incretin system is an area of great interest for the development of new therapies for the
management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting …